Soluble RAGEs and cardiovascular risk factors in adult offspring of patients with premature coronary heart disease

References

• Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA. 2005;294(24):3117–3123.
   PubMed Web of Science ®Google Scholar
• Nasir K, Budoff MJ, Wong ND, et al. Family history of premature coronary heart disease and coronary artery calcification: multi-ethnic study of atherosclerosis (MESA). Circulation. 2007;116(6):619–626.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Nam BH, D’Agostino RB, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004;291(18):2204–2211.
   PubMed Web of Science ®Google Scholar
• Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597–605.
   PubMed Web of Science ®Google Scholar
• Kalousova M, Zima T, Tesař V, at al. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res. 2005;579(1/2):37–46.
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625.
   PubMed Web of Science ®Google Scholar
• Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;352(12):836–842.
   Google Scholar
• Salahuddin P, Rabbani G, Khan RH. The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach. Cell Mol Biol Lett. 2014;19(3):407–437.
   PubMed Web of Science ®Google Scholar
• Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basis mechanisms to clinical implication. Atherosclerosis. 2008;196(1):9–21.
   PubMed Web of Science ®Google Scholar
• Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular disease. Mol med. 2007;13(11/12):625–635.
   PubMed Web of Science ®Google Scholar
• Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end-products. Nat Med. 1998;4(9):1025–1031.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci. 2010;2:1184–1195.
   Google Scholar
• Yan SF, D´Agati V, Schmidt AM. Receptor for advanced glycation endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes and aging. Curr Mol Med. 2007;7:699–710.
   PubMed Web of Science ®Google Scholar
• Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23(9):1725–1729.
   PubMed Web of Science ®Google Scholar
• Mayer O, Seidlerová J, Filipovský J, et al. Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. Hypertens Res. 2016;39(4):266–271.
   PubMed Web of Science ®Google Scholar
• Falcone C, Emanuele E, D´Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. ATVB. 2005;25(5):1032–1037.
   Google Scholar
• Cífková R, Škodová Z, Lánská V, et al. Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA study. J Hum Hypertens. 2004;18(8):571–579.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112(17):2735–2752.
   PubMed Web of Science ®Google Scholar
• Wohlfahrt P, Krajčoviechová A, Seidlerová J, et al. Lower-extremity arterial stiffness vs. aortic stiffness in the general population. Hypertens Res. 2013;36(8):718–724.
   PubMed Web of Science ®Google Scholar
• Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–448.
   PubMed Web of Science ®Google Scholar
• Wilkinson IB, Fuchs SA, Jansen IM, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens. 1998;16(Suppl):2079–2084.
   PubMedGoogle Scholar
• Prasad K, Dhar I, Caspar-Bell G. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol. 2015;24:75–80.
   PubMed Web of Science ®Google Scholar
• Stern DM, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev. 2002;1(1):1–15.
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA. 1994;91(19):8807–8811.
   PubMed Web of Science ®Google Scholar
• Mahajan N, Malik N, Bahl A, et al. Correlation among soluble markers and severity of disease in non-diabetic subjects with pre-mature coronary artery disease. Mol Cell Biochem. 2009;330(1/2):201–209.
   PubMed Web of Science ®Google Scholar
• Cohen R, Budoff M, McClelland RL, et al. Significance of a positive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the multi-ethnic study of atherosclerosis). Am J Cardiol. 2014;114(8):1210–1214.
   PubMed Web of Science ®Google Scholar
• Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–2605.
   PubMed Web of Science ®Google Scholar
• Tan KC, Shiu SW, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products in type 2 diabetes. Diabetologia. 2006;49(11):2756–2762.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yamagishi SI, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev. 2007;23(5):368–371.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011;60(9):2379–2385.
   PubMed Web of Science ®Google Scholar
• Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227(2):425–458.
   PubMed Web of Science ®Google Scholar
• Kalousová M, Hodková M, Kazderová M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47(3):406–411.
   PubMed Web of Science ®Google Scholar
• Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol. 2014;23(1):11–16.
   PubMedGoogle Scholar
• Corica D, Aversa T, Ruggeri RM, et al. Could AGE/RAGE-related oxidative homeostasis dysregulation enhance susceptibility to pathogenesis of cardio-metabolic complications in childhood obesity? Front Endocrinol. 2019;10:426.
   PubMed Web of Science ®Google Scholar
• Prasad K, Mishra M. AGE–RAGE stress, stressors, and antistressors in health and disease. Int J Angiol. 2018;27:1–12.
   PubMed Web of Science ®Google Scholar
• Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911–916.e12.
   PubMedGoogle Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;17:CIR0000000000000678.
   Google Scholar
• Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002;13(10):2478–2487.
   PubMed Web of Science ®Google Scholar
• Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm. 2009;2009:752406.
   PubMedGoogle Scholar
• Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986;232(4758):1629–1632.
   PubMed Web of Science ®Google Scholar